trending Market Intelligence /marketintelligence/en/news-insights/trending/GJj2jt3E4SFxdp7-sJntlA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

CSPC Pharmaceutical subsidiary receives approval to list in Shenzhen

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


CSPC Pharmaceutical subsidiary receives approval to list in Shenzhen

Hong Kong-listed CSPC Pharmaceutical Group Ltd. said it received approval from the China Securities Regulatory Commission to list CSPC XNW Pharmaceutical Joint Stock Company Ltd and its subsidiaries on Chinext, a Nasdaq-style board of the Shenzhen Stock Exchange.

CSPC XNW is an indirect non-wholly owned subsidiary of CSPC that manufactures and sells caffeine, vitamin C health supplements, and beverage products.

The listing is subject to obtaining formal written approval and other processes.